Patent intelligence · US
US 10617663
Dosage forms and therapeutic uses of L-4-chlorokynurenine
Dosage forms and therapeutic uses of L-4-chlorokynurenine
Patent details — US 10617663
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 14, 2020
- Expiration
- Apr 9, 2040
- Applicant
- VISTAGEN THERAPUETICS, INC.
- Claims
- 9
- CPC classes
- A61K, A61K31/198, A61K9/0053, A61P
Quick answer
US 10617663 (Dosage forms and therapeutic uses of L-4-chlorokynurenine) is held by VISTAGEN THERAPUETICS, INC.. Status: granted. Granted Apr 14, 2020. Expires Apr 9, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- VISTAGEN THERAPUETICS, INC.
- Grant date
- Expiration
- Claims
- 9
- CPC classes
- A61K, A61K31/198, A61K9/0053, A61P, A61P25/14, A61P25/16
More from VISTAGEN THERAPUETICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12036198
Dosage forms and therapeutic uses of L-4-chlorokynurenine
granted -
US 10980758
Dosage forms and therapeutic uses of L-4-chlorokynurenine
granted -
US 10632091
Dosage forms and therapeutic uses of L-4-chlorokynurenine
granted -
US 9993453
Dosage forms and therapeutic uses L-4-chlorokynurenine
granted -
US 9993450
Dosage forms and therapeutic uses of L-4-chlorokynurenine
granted
Frequently asked questions
What is US patent 10617663?
US 10617663 (Dosage forms and therapeutic uses of L-4-chlorokynurenine) is held by VISTAGEN THERAPUETICS, INC.. Status: granted. Granted Apr 14, 2020. Expires Apr 9, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10617663?
VISTAGEN THERAPUETICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 6 pharmaceutical patents for this assignee.
When does US 10617663 expire?
Our index shows an expiration date of Apr 9, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.